SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — David Hume — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientDavid Hume
Date of birth1711-05-07
IdentifiersMRN HR-EN012-SYN-TD; SSN (made up) 000-12-3049
Document date1775-07-13
AuthorFiona Gallacher, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review four weeks after sigmoid colectomy. [S]

History of Present Illness

Mr. Hume returns four weeks after laparoscopic sigmoid colectomy with primary anastomosis. The liver MRI before surgery showed that the 9 mm lesion is a hemangioma, with no metastases. He went home on the third day. His stools are now formed, once or twice a day, with no blood, and his wounds have healed. He walks 20 minutes a day and is less tired since the two iron infusions. The pathology shows a pT3 N1a adenocarcinoma, with 1 of 22 lymph nodes involved, clear margins, and no lymphovascular or perineural invasion: stage IIIB. Dr. Mehta has advised three months of adjuvant CAPOX, starting next week, and sent a DPYD genotype test before the first capecitabine dose. He has been offered genetic counseling. [S]

ElementDetail
Interval changeColectomy four weeks ago; home on the third day
Bowel functionFormed stools once or twice a day; no bleeding
PathologypT3 N1a (1 of 22 nodes), R0, stage IIIB
FunctionWalking 20 minutes a day; energy improving
Plan from oncologyCAPOX for three months from next week

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy improving; no fever
GastrointestinalNegativeFormed stools; no bleeding, pain, or urgency
IntegumentaryNegativeWounds healed
NeurologicalNegativeNo numbness or tingling of the hands or feet
PsychiatricNegativeMood good; PHQ-2 score 1; coping well

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Ferric carboxymaltose 750 mg intravenous infusion, two doses one week apart750 mg IV once a week for two dosesIntravenous route1775-06-01 to 1775-06-08completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1775-07-13Body height178cmS
1775-07-13Body weight82.5kgS
1775-07-13Body mass index (BMI) [Ratio]26kg/m2S
1775-07-13Systolic blood pressure124mm[Hg]S
1775-07-13Diastolic blood pressure76mm[Hg]S
1775-07-13Heart rate78/minS
1775-07-13Respiratory rate16/minS
1775-07-13Body temperature36.6CelS
1775-07-13Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1775-07-13Carcinoembryonic Ag [Mass/volume] in Serum or Plasma2.2ng/mL<=3 ng/mLNormalS
1775-07-13Hemoglobin [Mass/volume] in Blood12.4g/dL13.2-16.6 g/dLLowS
1775-07-13MCV [Entitic mean volume] in Red Blood Cells by Automated count82fL80-100 fLNormalS
1775-07-13Leukocytes [#/volume] in Blood by Automated count6.810*3/uL4-11 10*3/uLNormalS
1775-07-13Neutrophils [#/volume] in Blood by Automated count4.110*3/uL1.5-7.7 10*3/uLNormalS
1775-07-13Platelets [#/volume] in Blood by Automated count31210*3/uL150-400 10*3/uLNormalS
1775-07-13Ferritin [Mass/volume] in Serum or Plasma186ng/mL30-400 ng/mLNormalS
1775-07-13Iron saturation [Mass Fraction] in Serum or Plasma24%20-50%NormalS
1775-07-13Creatinine [Mass/volume] in Serum or Plasma0.96mg/dL0.74-1.35 mg/dLNormalS
1775-07-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1770)/1.73 sq M88mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1775-07-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L7-55 U/LNormalS
1775-07-13Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
1775-07-13Albumin [Mass/volume] in Serum or Plasma3.9g/dL3.5-5 g/dLNormalS
1775-07-13Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Physical Exam

Vital signs recorded on 1775-07-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell, better color
AbdomenPort-site scars healed; soft, non-tender; no hernia
NeurologicalBaseline before oxaliplatin: light touch, vibration, and proprioception normal in hands and feet; ankle reflexes present
SkinPalms and soles normal before capecitabine

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the sigmoid colon, suspected at presentation and confirmed by colonoscopic biopsy; synthetic modern diagnosis linked to the documented 1775 bowel disorder and its retrospective interpretation as colon canceractiveconfirmed C18.7S — Synthetic diagnosis confirmed by biopsy and resection in the modern episode; the historical diagnosis remains a retrospective interpretation (R).
Iron deficiency anemia from chronic blood loss from the colon tumoractiveconfirmed D50.0S — Synthetic finding echoing the documented 'hemorrhage in the upper part of the intestines'; no blood count from his lifetime exists.
Hemangioma of the liver, 9 mm, segment VI; incidental finding characterized by MRI, not a metastasisactiveconfirmed D18.03S — Synthetic incidental finding; it addresses, and does not confirm, the unverified suggestion of liver spread.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryCEA after resectionEvery 3 to 6 months for 2 yearsCompleted today2.2 ng/mL, normal, down from 6.4 before surgery
LaboratoryBlood count and iron studies 6 to 8 weeks after intravenous ironOnce after infusionCompleted todayHemoglobin 12.4 g/dL, MCV 82 fL; ferritin 186 ng/mL, transferrin saturation 24 percent; neutrophils 4.1 and platelets 312 before chemotherapy
LaboratoryKidney and liver function before chemotherapyBefore each cycle (oncology)Completed todayCreatinine 0.96 mg/dL, eGFR 88; ALT 20 U/L, bilirubin 0.5 mg/dL, albumin 3.9 g/dL
SurveyDistress and depression screen (PHQ-2)At each follow-up visitCompleted todayPHQ-2 score 1; coping well
SurveyDistress screen missed at the diagnosis visitAt each follow-up visitDeferredMissed at the visit three weeks after presentation, a deviation from the protocol. Today's screen is negative and he reports coping well, so no harm is evident; the screen is now on his visit checklist
ImagingMRI of the liverOnce, for the indeterminate CT lesionUp to dateDone before surgery: hemangioma; no metastases
ImagingCT of the chest, abdomen, and pelvisEvery 6 to 12 months for 5 yearsDueFirst surveillance scan about six months after surgery
ExaminationHistory and examination, wound and bowel functionEvery 3 to 6 months for 2 yearsCompleted todayWounds healed; formed stools; no ostomy
ExaminationPeripheral neuropathy baselineBefore and at every visit during and after oxaliplatinCompleted todayNormal sensation and reflexes before the first dose
Medication safetyDPYD genotype before capecitabineOnce, before the first doseOrderedSent by the oncology team; the result will be reviewed before cycle 1
ReferralGenetic counseling for germline testingAt diagnosis of colorectal cancer, especially with a family historyReferredOffered because his mother is reported to have died of a similar bowel illness; tumor mismatch-repair proficient
Self-managementPhysical activityEvery visitCompleted todayWalking 20 minutes a day; goal of 150 minutes a week through chemotherapy

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, Version 4.2025 (2025); Duration of Adjuvant Chemotherapy for Stage III Colon Cancer (IDEA collaboration). N Engl J Med 2018;378:1177-1188 (2018); AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia (2020); CMID: Clinical Monitoring Intelligence Database, colorectal cancer and anemia monographs (2026)

Follow-up: CAPOX cycle 1 next week with the oncology team. Primary care review after the fourth cycle, with blood count, CEA, and a neuropathy check. Next scheduled visit 1775-10-19: review two weeks after completing adjuvant CAPOX and start of survivorship surveillance. [S]